

Evaluation of Pharmaceutical Optimized Atenolol 50mg (F-9) with Essential Hypertension

1. Moula Bux 2. Abdul Latif 3. Shereen Mohammad 4. Asnad 5. Muhammad Ishaq

1. Assoc. Prof. of Biochemistry, 2. Prof. of Pharmacology, 3. Prof. of Biochemistry, 4. Asstt. Prof. of Biochemistry, 5. Prof. of Surgery, Jinnah Medical College Peshawar

ABSTRACT

Objective: The objective of this double-blind, Placebo control study evaluating efficacy and biochemical effects of optimized Atenolol 50mg (F-9) as monotherapy in adult patient with essential hypertension.

Study Design: Double-blind, Placebo control study.

Place and Duration of Study: This study was conducted at the Department of Biochemistry, University of Karachi from February 2011 to September 2011.

Materials and Methods: This was multicenter randomized, double-blind, Placebo control study. Patients were randomized to receive once Atenolol (F-9) daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done

Results: The patients treated with optimized Atenolol 50mg (F-9) alone, blood pressure reduction was lower, although significant; reaching values of 140.9 ± 11.3 / $m88.9 \pm 5.5$ mmHg ($p < 0.05$ versus Placebo) by the end of eight weeks of treatment. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses.

Conclusion: We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Atenolol 50mg (F-9) it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks.

Key Words: Hypertension, Atenolol, Biochemical effects

INTRODUCTION

Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality¹. In European countries the prevalence of hypertension in adults is estimated to be approximately 44%.² Current guidelines for the management of hypertension recommend a target blood pressure of 140/90 mmHg, with a stricter target for patients who have a high risk of cardiovascular events ($< 130/80$ mmHg).^{3,4}

Atenolol is a β_1 -receptor selective antagonist and is mainly used in treating hypertension, angina, heart failure and myocardial infarction; chemically, it is 4-(2-hydroxyl-3-isopropyl aminopropoxy) phenylacetamide.^{5,6} The physicochemical properties of atenolol, i.e., slight water solubility, low molecular weight (266.336), and its suitable elimination half-life ($t_{1/2} = 6-7$ h).⁶

Comparative safety and efficacy trials indicate that angiotensin receptor blockers like olmesartan medoxomil have superior tolerability and antihypertensive efficacy⁷. Similar investigation using olmesartan, medoxomil and amlodipine besylate showed great effectiveness and tolerance in patient with hypertension⁸. Combination therapies reduced B.P to a

greater extent than with amlodipine besylate alone as indicated with benazepril hydrochloride with valsartan and with perindopril^{9, 10}.

Therefore, the objective of this comparative study evaluating the efficacy and biochemical effects of optimized Atenolol 50mg (F-9) with placebo in the treatment of patients with essential hypertension.

MATERIALS AND METHODS

This was multicenter, randomized, placebo-controlled study. Patient was randomized to receive optimized Atenolol 50mg (F-9) once daily and Placebo once daily for 8 weeks. The study was conducted in Department of Biochemistry, University of Karachi from February 2011 to September 2011, Patients were selected from four different hospitals of orange Town and 80 patients were selected for the study. Therefore 80 patients were effectively analyzed for efficacy and tolerability the analysis of antihypertensive efficacy and biochemical effects of a therapeutic regimen in the long term becomes important. The primary efficacy variable was change from baseline in MSDP at the end of study. Secondary variable was change in mean sitting systolic blood pressure from baseline. Safety biochemical parameters (complete blood count, renal function, liver function, electrolytes, protein profile, and enzymes) and electrocardiogram at rest were also determined in all

patients at the baseline (week 0) and at the 8th week of antihypertensive treatment. At the same time points, glucose metabolism parameter values and plasma lipids (total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides) were also recorded. Biochemical parameters were determined using an automated method.

RESULTS

The patients treated with optimized Atenolol 50mg (F-9) alone, blood pressure reduction was lower, although significant; reaching values of 140.9 ± 11.3 / 88.9 ± 5.5 mmHg ($p < 0.05$ versus Placebo) by the end of eight weeks of treatment. Variations in blood pressure measurement in the standing position during treatment were similar to those recorded in the sitting position, and no episode of orthostatic hypotension was reported in either of the therapeutic regimen. No significant variation in leg volume measurement was observed among the both groups studied during the eight weeks of treatment. No significant variations of blood glucose were observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses.

Table No.1: Baseline characteristics

	Atenolol (F-9) (n=60)	Placebo (n=20)
Age (years)	50.2 ± 9.3	51.5 ± 9.8
Male / Female (%)	43.4 / 56.6	35.0 / 65.0
Body weight (Kg)	68.9 ± 13.5	71.2 ± 12.2
BMI (kg/m ²)	27.5 ± 3.8	27.8 ± 3.4
SBP sitting (mmHg)	149.5 ± 11.5	148.8 ± 10.9
DBP sitting (mmHg)	95.7 ± 7.4	94.9 ± 7.8

**Table No.2 Ambulatory blood pressure monitoring.
Mean values of blood pressure**

	Atenolol (F-9) (n=60)	Placebo (n=20)	P-value
Systolic BP – 24 hrs (mmHg)			
Baseline	149.8 ± 11.2	149.2 ± 11.5	NS
Week 8	140.9 ± 11.3	148.9 ± 11.2	0.0074
Diastolic BP – 24 hrs (mmHg)			
Baseline	97.6 ± 7.4	95.4 ± 8.8	NS
Week 8	88.9 ± 5.5	94.9 ± 7.9	0.0003

NS: Non significant, p: probability

Table No.3: Baseline Biochemical characteristics

	Atenolol (F-9) (n=60)	Placebo (n=20)
Fasting Blood Glucose(mg/dl)		
Baseline	97.4 ± 11.5	99.1 ± 8.8
Week 8	95.5 ± 11.9	98.9 ± 9.2
Total Cholesterol (mg/dl)		
Baseline	197.2 ± 43.2	195.2 ± 33.3
Week 8	199.7 ± 43.5	193.9 ± 34.1
LDL - Cholesterol (mg/dl)		
Baseline	114.4 ± 34.1	117.9 ± 25.9
Week 8	114.9 ± 34.5	116.8 ± 24.7
HDL - Cholesterol (mg/dl)		
Baseline	52.9 ± 13.1	48.9 ± 11.7
Week 8	51.8 ± 12.8	48.7 ± 11.5
Triglycerides (mg/dl)		
Baseline	137.2 ± 88.5	145.5 ± 88.1
Week 8	136.1 ± 89.3	144.2 ± 88.9

DISCUSSION

The baseline characteristics of the population included in the study are shown in Table no1. We can observe that the groups were not different in relation to age, body mass index and weight, heart rate, and systolic and diastolic pressure values. No significant variations of blood glucose and different parameters of lipid profile were observed during the eight-week of treatment with any of the three antihypertensive regimens used. Thus, the drug regimens used may be considered neutral as regards glucose, plasma lipid metabolism. The results of this study showed that the optimized product Atenolol 50mg (F-9) as a high antihypertensive efficacy that is sustained in the long term with a quite reduced percentage of loss of blood pressure control in table No.2 We observed that more than 71.8% of the patients treated with optimized product of Atenolol 50mg (F-9) remained with diastolic blood pressure levels equal to or lower than 90 mmHg, thus achieving the goals for the treatment of hypertension. The difficulty to achieve the goal of controlling systolic blood pressure explains why the international guidelines for studies on antihypertensive drugs still use criteria based on diastolic blood pressure to describe the antihypertensive efficacy of a drug, in spite of the fact that guidelines indicate the real need to control systolic blood pressure as well. It is important to point out that blood pressure reduction provided by the treatment with optimized product of Atenolol 50mg (F-9) did not cause any secondary Increase in sympathetic activity, since no significant variations of heart rate occurred. In addition to a high efficacy in reducing blood pressure, keeping it at controlled levels, an antihypertensive drug should also have a good biochemical profile, since the presence of adverse effects may decrease the degree of compliance of the patient to the therapeutic regimen, thus ultimately

leading to treatment dropout. Our results showed that the optimized product of Atenolol 50mg (F-9) at low doses has a very good biochemical profile with a low incidence of adverse events. The good biochemical profile of the optimized Atenolol 50mg (F-9) may be explained by the use of lower doses of each of the hypotensive drugs, since the existence of a strong relation between the dose of the hypotensive drug and the frequency of adverse events is known. However, some drugs used in the treatment of hypertension, such as diuretics and beta-blockers, are known to be able to promote harmful alterations in lipid metabolism, especially in glucose metabolism. In our study we observed that the use of the optimized Atenolol 50mg (F-9) did not change parameters of either glucose metabolism or plasma lipids, thus having a neutral biochemical profile even when used for 8 weeks. Table.No.3 Based on these results we can suggest that the optimized product Atenolol 50mg (F-9) is safe and adequate for the treatment of hypertension in patients with metabolic syndrome, diabetes mellitus and dyslipidemia; because alterations in these parameters are very frequently observed in hypertensive patients. Incidentally, hypertension is frequently associated to the metabolic syndrome; also, the frequency of this association increases with age. However, some drugs used in the treatment of hypertension, such as diuretics and beta blockers, are known to be able to promote harmful alterations in lipid metabolism, especially in glucose metabolism. Based on these results we can suggest that this therapeutic modality is safe and adequate for the treatment of hypertension in patients with metabolic syndrome, diabetes mellitus and dyslipidemia.

CONCLUSION

In brief, the results of this multicenter study demonstrated that the optimized Atenolol 50mg (F-9) has a high antihypertensive efficacy, allowing approximately 72.1% of the patients treated to achieve and maintain for eight weeks. We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Atenolol 50mg (F-9) it is an excellent option for the treatment of hypertension.

REFERENCES

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. For the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. *Lancet* 2002;360:1347–60.
2. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension and blood pressure levels in 6 European countries, Canada, and the US. *JAMA* 2003;289:2363–9.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003;42: 1206 – 1252.
4. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). *Hypertens Res* 2009; 32: 3 – 107.
5. Budavari S. The Merck Index, 13th ed. Merck & Co. Inc. Whitehouse Station: NJ; 2001, p.147.
6. The Indian Pharmacopoeia. The Controller of Publications. Ministry of Health. Govt. of India. New Delhi 1996, p.1-72.
7. Steven GC, Michael M, Sulekha K, James L, Reinilde H. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. *Clin Therapeut* 2008;30: 587-604.
8. Bernard RC, Carl JP, John OP, Jaroslav SI, Galina C, Jerzy K, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. *JAMA* 2004; 291: 309-316.
9. Khalida B, Najaf AG, Naheed A. Comparative studies of cimetidine derivative “temalastine” for potential energy calculation by Kitaigorodskii and Lennard-Jones functions. *Pak J Biochem Mol Biol* 2010; 43: 81-86.
10. Afshan N, Naheed A, Khalida B, Najaf AG and Farhat B. Conformational analysis geometry optimization) of nucleosidic antitumor antibiotic showdomycin by Arguslab 4 software. *Pak J Pharmacol* 2009;22:78-82.

Address for Corresponding Author:

Prof. Dr. Muhammad Ishaq

Chairman & Founder

Jinnah Medical College Warsak Road, Peshawar.

Contact No: 0333-9152060